Falcon III Ventures
VC Fund
Boston, United States
Falcon III Ventures is a VC fund in Boston focused on Biotechnology and Bioinformatics. Falcon III Ventures Boston-based biotech Venture capital.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Falcon III Ventures invests in
Stages Falcon III Ventures invests in
Countries Falcon III Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 2 (67%)
- Bioinformatics 2 (67%)
- Machine Learning 2 (67%)
- Artificial Intelligence 2 (67%)
- Genetics 1 (33%)
Stage
- Seed 1 (33%)
- Funding Round 1 (33%)
- Venture - Series Unknown 1 (33%)
Country
- Switzerland 1 (33%)
- United States 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Yiannis Monovoukas
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biotia
|
Biotia is a health tech company spun out of Cornell Tech leveraging next-generation sequencing and artificial intelligence for rapid and precise infectious disease discovery. Their software and laboratory technology enable clinicians and researchers to guide patient treatment and improve health outcomes. | $2.4M / Seed / Dec 10, 2019 | |
InterAx Biotech Ltd
|
InterAx is pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health. InterAx is a Swiss biotech company, spinoff of ETH Zurich and Paul Scherrer Institute incorporated in 2016, reinventing drugdiscovery to significantly reduce the time and costs associated with the discovery and development of new drugs for a wide array of human diseases. Our solution lies in the combination of in-house experimental assays, mathematical modelling and artificial intelligence to analyze and predict the physiological response of cells to drugs. We are able to describe the complex action of drug molecules in their cellular context and to guide the optimization of drug candidates to achieve a specific cellular response leading to higher efficacy and reduced side effects in humans, thus significantly accelerating drug discovery and de-risking clinical trials. | $3.5M / Jan 15, 2019 | |
|
InterAx Biotech Ltd
|
InterAx is pioneering a new scientific discipline at the intersection of biology and machine learning with the aim to be on the forefront of the digital transformation of drug discovery and ultimately improve human health. InterAx is a Swiss biotech company, spinoff of ETH Zurich and Paul Scherrer Institute incorporated in 2016, reinventing drugdiscovery to significantly reduce the time and costs associated with the discovery and development of new drugs for a wide array of human diseases. Our solution lies in the combination of in-house experimental assays, mathematical modelling and artificial intelligence to analyze and predict the physiological response of cells to drugs. We are able to describe the complex action of drug molecules in their cellular context and to guide the optimization of drug candidates to achieve a specific cellular response leading to higher efficacy and reduced side effects in humans, thus significantly accelerating drug discovery and de-risking clinical trials. | $3M / Venture - Series Unknown / Jan 15, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Falcon III Ventures invest in?
Falcon III Ventures invests primarily in Biotechnology, Bioinformatics and Machine Learning startups, most often at Seed and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Falcon III Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Falcon III Ventures?
The team at Falcon III Ventures includes Yiannis Monovoukas (Co-Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
